Richardson Kelli M, Schembre Susan M, Jospe Michelle R, Widmer Annaliese, Silver Heidi J
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Diabetes Obes Metab. 2025 Jul;27(7):3725-3735. doi: 10.1111/dom.16395. Epub 2025 Apr 21.
To evaluate changes in dietary intake following liraglutide treatment, compared to dietitian-supported caloric restriction and a weight-neutral control, and to assess dietary intake against nutrition recommendations.
Participants with obesity and prediabetes were randomly assigned 2:1:1 to liraglutide (1.8 mg/day), dietitian-supported caloric restriction (-390 kcals/day) or dipeptidyl peptidase-4 inhibitor (100 mg/day) for 14 weeks. Dietary intake was assessed via a single 24-h dietary recall pre- and postintervention. Within-group changes and between-group differences in macronutrient and micronutrient intake, diet quality and food sources were evaluated, and the proportion of participants meeting nutrition recommendations was calculated.
Seventy participants (69% female, 83% white) were included. Average age was 49.4 ± 11.3 years, and mean BMI was 39.5 ± 6.1 kg/m. Significant differences in change in percent calories from protein (p = 0.037), carbohydrates (p = 0.019) and added sugar (p = 0.002) were observed across groups, with those in the caloric restriction group having the greatest increase in protein and decreases in carbohydrates and added sugar. Micronutrient intake did not significantly differ between groups nor did Total Healthy Eating Index (HEI)-2020 scores. However, the caloric restriction group significantly improved their HEI component score for added sugar compared to the liraglutide group (p = 0.002) when adjusted for baseline intake. Despite the treatment group, participants failed to meet several of the same nutrition recommendations, including those for fruit, vegetable and dairy intake.
Overall diet quality was poor across all groups. However, the caloric restriction group significantly reduced its added sugar intake, highlighting a potential benefit nutrition counselling may have for AOM users. Future research is needed to examine the long-term impact of AOM use on dietary intake, with and without nutrition guidance, to better inform clinical recommendations.
评估与营养师支持的热量限制和体重中性对照相比,利拉鲁肽治疗后饮食摄入量的变化,并根据营养建议评估饮食摄入量。
将肥胖和糖尿病前期参与者按2:1:1随机分配至利拉鲁肽组(1.8毫克/天)、营养师支持的热量限制组(-390千卡/天)或二肽基肽酶-4抑制剂组(100毫克/天),为期14周。通过干预前后单次24小时饮食回顾评估饮食摄入量。评估组内宏量营养素和微量营养素摄入量、饮食质量和食物来源的变化以及组间差异,并计算符合营养建议的参与者比例。
纳入70名参与者(69%为女性,83%为白人)。平均年龄为49.4±11.3岁,平均体重指数为39.5±6.1千克/米²。各组之间蛋白质(p = 0.037)、碳水化合物(p = 0.019)和添加糖(p = 0.002)的热量百分比变化存在显著差异,热量限制组蛋白质增加最多,碳水化合物和添加糖减少最多。组间微量营养素摄入量和2020年总健康饮食指数(HEI)得分无显著差异。然而,在根据基线摄入量进行调整后,热量限制组与利拉鲁肽组相比,其添加糖的HEI成分得分显著提高(p = 0.002)。尽管有治疗组,但参与者仍未达到多项相同的营养建议,包括水果、蔬菜和乳制品摄入量的建议。
所有组的总体饮食质量都很差。然而,热量限制组显著降低了其添加糖摄入量,突出了营养咨询对使用抗肥胖药物(AOM)者可能具有的潜在益处。需要进一步研究以检查使用AOM对饮食摄入量的长期影响,有无营养指导,以便更好地为临床建议提供依据。